# A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients

> **NCT05662956** · PHASE2 · COMPLETED · sponsor: **Hematology department of the 920th hospital** · enrollment: 114 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax in combination with azacitidine and CAG

## Key facts

- **NCT ID:** NCT05662956
- **Lead sponsor:** Hematology department of the 920th hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05662956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05662956, "A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05662956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*